This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TScan Therapeutics’s 8K filing here.
TScan Therapeutics Company Profile
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Featured Stories
- Five stocks we like better than TScan Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Battle of the Retailers: Who Comes Out on Top?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What does consumer price index measure?
- MarketBeat Week in Review – 10/28 – 11/1
